The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17β‐hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma
- 2 June 2003
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 58 (6) , 696-703
Abstract
Summary: objective In situ metabolism and synthesis of oestrogens are considered to play important roles in the pathogenesis and development of human endometrial endometrioid adenocarcinoma. Approximately 3–5% of patients with these neoplasms are under age 40, some of whom have been treated with progestogen alone as a primary therapy for both atypical endometrial hyperplasia and adenocarcinoma in order to preserve their fertility. Medroxyprogesterone acetate (MPA) has been used extensively in the treatment of both breast and endometrial disorders as an endocrine therapy. However, details of the alterations of in situ oestrogen metabolism following progestogen treatment have yet to be fully elucidated.design, patients and measurements In this study we examined the immunolocalization of 17β‐hydroxysteroid dehydrogenase (17β‐HSD) types 1 and 2, oestrogen receptor (ER), progesterone receptor (PR)A + PRB, PRB, and Ki67 in progestogen‐treated endometrial endometrioid adenocarcinoma (16 cases). We compared our findings both prior to and following treatment. These findings were then correlated with the treatment outcome of individual patients in order to elucidate factors associated with the response to treatment.results 17β‐HSD type 2 immunoreactivity was detected in 8/16 cases examined, whereas 17β‐HSD type 1 immunoreactivity was undetected in all cases examined. 17β‐HSD type 2 positive immunostaining, PRA + PRB labelling index (LI), and PRB/PRA + PRB ratio were all significantly higher in cases responding to the treatment than in those not responding. There were no significant correlations between responsive and nonresponsive cases for positive 17β‐HSD type 1 immunostaining, Ki67 LI, ER LI and age. There were no significant differences in the positive immunostaining for 17β‐HSD types 1 and 2, Ki67 LI, ER LI, PRA + PRB LI, age and PRB/PRA + PRB ratio between specimens taken prior to and following progestogen treatment.conclusion These results suggest that in situ abundance of 17β‐HSD type 2 and PR, especially PRB, can predict the possible response of patients with endometrial carcinoma to progestogen treatment.Keywords
This publication has 43 references indexed in Scilit:
- The Analyses of 17 -Hydroxysteroid Dehydrogenase Isozymes in Human Endometrial Hyperplasia and CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2001
- Which form of HRT should we choose?Clinical Endocrinology, 1998
- Progestin alone as primary treatment of endometrial carcinoma in premenopausal womenCancer, 1997
- Cancer statistics, 1996CA: A Cancer Journal for Clinicians, 1996
- Role of 17β-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesisThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional acitivityThe Journal of Steroid Biochemistry and Molecular Biology, 1994
- Molecular action of progesteroneInternational Journal of Biochemistry, 1990
- Complete amino acid sequence of human placental 17β‐hydroxysteroid dehydrogenase deduced from cDNAFEBS Letters, 1988
- Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal EndometriumNew England Journal of Medicine, 1981
- Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancerBreast Cancer Research and Treatment, 1981